Elevation of serum soluble tumour necrosis factor receptors in patients with polymyositis and dermatomyositis
- PMID: 11055823
- DOI: 10.1007/s100670070027
Elevation of serum soluble tumour necrosis factor receptors in patients with polymyositis and dermatomyositis
Abstract
The aim of the study was, to examine the relationship between serum levels of soluble tumour necrosis factor receptors (sTNF-R) and the gene expression of two types of receptor for TNF (TNF-R), a 55 a receptor (TNF-R1) and a 75 kDa receptor (TNF-R2), bloodin peripheral mononuclear cells (PBMC) from patients with polymyositis and dermatomyositis (PM/DM). Soluble tumour necrosis factor receptor 1 (sTNF-R1) and soluble tumour necrosis factor receptor 2 (sTNF-R2) levels in sera from patients were measured by enzyme-linked immunosorbent assay. Expression of TNF-R1 and TNF-R2 mRNAs in PBMC was analysed by Northern blotting. Serum sTNF-R1 and sTNF-R2 levels were elevated significantly in 25 patients with active-stage PM/DM, compared to those in 18 patients with inactive-stage PM/DM and 32 normal controls. Serum concentrations of sTNF-R1 and sTNF-R2 were correlated with PM/DM disease activity. TNF-R1 gene expression was enhanced in freshly isolated PBMC from patients with active-stage PM/DM. In contrast, TNF-R2 mRNA was expressed constitutively in patients with active-stage PM/DM and in normal controls. The expression of TNF-R1 and TNF-R2 mRNAs in PBMC and elevation of their soluble forms in the sera of patients with active-stage PM/DM suggest increased proteolytic cleavage of cell surface TNF-R from PBMC in patients with active-stage PM/DM, and that sTNF-R may regulate TNF-alpha-mediated muscle fibre damage in PM/DM.
Similar articles
-
Abnormal IL-1 receptor antagonist production in patients with polymyositis and dermatomyositis.Intern Med. 2000 Feb;39(2):128-35. doi: 10.2169/internalmedicine.39.128. Intern Med. 2000. PMID: 10732829
-
Elevated serum levels of neopterin in adult patients with polymyositis/dermatomyositis.Br J Rheumatol. 1997 Jun;36(6):656-60. doi: 10.1093/rheumatology/36.6.656. Br J Rheumatol. 1997. PMID: 9236675
-
Elevated serum levels of interleukin-1 receptor antagonist in polymyositis/dermatomyositis. A biologic marker of disease activity with a possible role in the lack of acute-phase protein response.Arthritis Rheum. 1994 Dec;37(12):1744-51. doi: 10.1002/art.1780371206. Arthritis Rheum. 1994. PMID: 7986220
-
PEGylated recombinant human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-RI): novel high affinity TNF receptor designed for chronic inflammatory diseases.Ann Rheum Dis. 1999 Nov;58 Suppl 1(Suppl 1):I73-81. doi: 10.1136/ard.58.2008.i73. Ann Rheum Dis. 1999. PMID: 10577978 Free PMC article. Review.
-
The role of tumor necrosis factor receptors in cell signaling and the significance of soluble form levels in the serum.Surg Today. 1994;24(3):197-202. doi: 10.1007/BF02032887. Surg Today. 1994. PMID: 8003860 Review.
Cited by
-
A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis.Semin Arthritis Rheum. 2018 Jun;47(6):858-864. doi: 10.1016/j.semarthrit.2017.10.010. Epub 2017 Oct 16. Semin Arthritis Rheum. 2018. PMID: 29174792 Free PMC article. Clinical Trial.
-
Targeted immunotherapy trials for idiopathic inflammatory myopathies.J Neurol. 2013 Feb;260(2):368-85. doi: 10.1007/s00415-012-6590-7. Epub 2012 Jun 30. J Neurol. 2013. PMID: 22752063 Review.
-
Treatment of early and refractory dermatomyositis with infliximab: a report of two cases.Clin Rheumatol. 2007 Jul;26(7):1186-8. doi: 10.1007/s10067-006-0325-z. Epub 2006 May 31. Clin Rheumatol. 2007. PMID: 16736125
-
Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients.Ann Rheum Dis. 2006 Sep;65(9):1233-6. doi: 10.1136/ard.2005.048744. Epub 2006 Feb 13. Ann Rheum Dis. 2006. PMID: 16476710 Free PMC article.
-
Comparison of cytokine/chemokine profiles between dermatomyositis and anti-synthetase syndrome.Front Neurol. 2022 Dec 8;13:1042580. doi: 10.3389/fneur.2022.1042580. eCollection 2022. Front Neurol. 2022. PMID: 36570445 Free PMC article.